TNF-α Blockade Mitigates Immune Checkpoint-Related Nephritis in a Humanized Mouse Model ⁦@JCI_insight⁩ @VictorCuenca3 @MayoClinicNeph @onconephsociety #onconephrology First Immunocompetent chimeric 🐁 Model of ICI-AIN ! pubmed.ncbi.nlm.nih.gov/4178…

Biomarker-driven Immunotherapy for Checkpoint Inhibitor-induced Interstitial Nephritis 🎙️Speaker: @HerrmannMd 🟠Acute Kidney Injury related to Immune Checkpoint Inhibitors remains a significant diagnostic challenge. 🟠Kidney biopsy is the gold standard to confirm the diagnosis, but its use in oncological patients requires a meticulous risk-benefit analysis. ⚖️ #ERA26

If you want to learn more about glomerular diseases, don’t miss this opportunity to hear from 🌍 world-renowned experts with unparalleled clinical experience check this out👇🏽@MayoClinicNeph directors @LadanZand @fervenzaf @LeticiaRolonMD

😊🙏🏻 Deeply honored to be recognized as a 2025 Top Reviewer for the Clinical Kidney Journal (CKJ) today at European Renal Association #ERA2026 in Glasgow! 🏆🏴󠁧󠁢󠁳󠁣󠁴󠁿 #ERA26 @ERAkidney @CKJsocial It was an absolute privilege to attend the CKJ Editorial Board Meeting, meet Editor-in-Chief Professor Jürgen Floege in person, and hear about the journal’s impressive achievements over the past year and its exciting vision for the future. Peer review is the fundamental engine that drives science forward and improves patient care. I am especially grateful for the opportunity to serve as a reviewer evaluating manuscripts focused on artificial intelligence and machine learning in nephrology. It is a profound responsibility to help vet the innovative research that is actively shaping the future of clinical decision-making, medical education, and advanced kidney care. A sincere thank you to Professor Floege, the CKJ Editorial Board, and the entire editorial team for their stellar leadership and dedication to publishing high-quality clinical and translational research. CKJ truly continues to be a premier platform for scientific innovation. Congratulations to all of my fellow reviewers and award recipients! Your expertise and unwavering commitment are what keep our scientific community strong and advance kidney health worldwide. 🙏😀 @CKJsocial @ERAkidney Wisit Cheungpasitporn, MD, FACP, FASN, FAST Clinician-Scientist & Professor of Medicine, Mayo Clinic Leading AI Innovation in Kidney Care @MayoClinicNeph #ERA2026 #ClinicalKidneyJournal #CKJ #Nephrology #KidneyCare #PeerReview #MedicalResearch #ArtificialIntelligence #MachineLearning #AIinMedicine #NephrologyAI #MedicalEducation #AcademicMedicine #Glasgow #KidneyHealth

😊👏👏 Outstanding presentation by our world-renowned consultant, Fernando Fervenza, at the Late Breaking Clinical Trials session during the 63rd ERA Congress in Glasgow. #ERA2026 #ERA26 European Renal Association @ERAkidney @fervenzaf at Late Breaking Clinical Trial Session The Phase III MAJESTY Trial compared obinutuzumab versus tacrolimus in primary membranous nephropathy, addressing a critical unmet need in glomerular disease. It was inspiring to see a packed auditorium and tremendous engagement as these landmark results were presented to the international nephrology community. 👏👏🎉🙂 Congratulations to Dr. Fervenza and the entire MAJESTY Trial team for advancing the field and bringing new hope to patients with primary membranous nephropathy. Exciting times ahead for precision therapies in glomerular diseases. We, at Mayo Clinic Nephrology, are proud to see Dr. Fervenza continue to lead groundbreaking clinical research that advances patient care and shapes the future of glomerular disease treatment worldwide. @MayoClinicNeph @HerrmannMd #ERA2026 #Nephrology #GlomerularDisease #MembranousNephropathy #MAJESTYTrial #ClinicalTrials #KidneyDisease #MayoClinic #ERACongress #KidneyResearch

Congratulations Dr @fervenzaf and team: Obinituzumab vs Tacrolimus for MN @NEJM @MayoClinicNeph 👏👏

😊👏👏 Prof. Fernando Fervenza presenting the Phase III MAJESTY Trial at the Late Breaking Clinical Trials session at #ERA2026. @fervenzaf @ERAkidney #ERA26

Outstanding presentation by Michele Barbarini @MBarbarini on immune checkpoint inhibitor–associated acute interstitial nephritis #ERA2026. Excellent work on urinary retinol-binding protein-to-creatinine ratio as a noninvasive biomarker for diagnosis and monitoring. 👏 @ERAkidney

Dr @kianoushbk presenting at #ERA26 AI in AKI & CRRT @MayoClinicNeph @ERAkidney

2/ 📌 Here are the main take-home messages #ERA26

1/Biomarkers are emerging as a highly promising, non-invasive tool to accurately diagnose immune checkpoint inhibitor-related complications. 🎯#ERA26

great talk at #era2026 by @HerrmannMd!

Wonderful presentation by Dr. Sandra Herrmann at #ERA2026 on “Biomarker-Driven Immunotherapy for Checkpoint Inhibitor–Induced Interstitial Nephritis.” @HerrmannMd

Onconephrology session at #ERA2026 happening now with Maridelina Simeoni presenting Electrolytes in onconephrology @ERAkidney

An absolute honor to meet Professor Jürgen Floege, Editor-in-Chief of the Clinical Kidney Journal (CKJ), in person here at #ERA2026 in Glasgow! 🏴󠁧󠁢󠁳󠁣󠁴󠁿✨ 🙏🏻😃 @CKJsocial @ERAkidney I am incredibly humbled and honored to be recognized as one of the Top Reviewers of the Year for CKJ, specifically for my work reviewing articles on Artificial Intelligence in nephrology. 🤗😃🙏🏻 Thank you to the editorial team for this recognition, and it is wonderful to connect with so many peers dedicated to advancing kidney health. Wisit Cheungpasitporn, MD, FACP, FASN, FAST Clinician-Scientist & Professor of Medicine, Mayo Clinic Leading AI Innovation in Kidney Care #ERA2026 #Nephrology @MayoClinicNeph #ClinicalKidneyJournal #CKJ #KidneyCare #MedicalResearch #MedicalEducation #PeerReview #Glasgow #ScienceCommunication #NephroAI

Congratulations 👏 María José Soler on an outstanding and highly engaging session on IgA nephropathy at ERA 2026. European Renal Association (ERA) @PepaSolerR @ERAkidney The auditorium was completely full, reflecting the tremendous interest in advancing patient-centered care, earlier diagnosis, and emerging therapeutic strategies for IgAN. It was inspiring to see experts, clinicians, and patient advocates come together to discuss the future of disease-specific management and improving outcomes for patients living with IgA nephropathy. #ERA2026 #IgAN #IgANephropathy #Nephrology #KidneyDisease #PatientCenteredCare #KidneyHealth #ERACongress #GlomerularDisease #NephrologyCommunity

😃🙏🏻 Honored to meet Professor Jürgen Floege, Editor-in-Chief of Clinical Kidney Journal (CKJ), in person at ERA 2026, in Glasgow, UK @CKJsocial @ERAkidney It was inspiring to hear his overview of CKJ’s impressive achievements over the past year and its exciting future direction. Under his leadership, CKJ continues to reach new heights in scientific quality, global influence, and academic impact, becoming one of the leading journals in nephrology. We are proud to support CKJ through peer review and scientific collaboration, helping advance kidney research, education, and patient care worldwide. @PepaSolerR @HerrmannMd @MayoClinicNeph

Good luck 🍀 on the East Coast, @VictorCuenca3! We hope to see you again at @MayoClinicNeph in the future!